Retatrutide trial details show weight and glucose reductions in type 2 diabetes

Detailed results released September 29 from the phase 3 TRIUMPH-2 trial show that retatrutide reduced weight and blood sugar in adults with overweight or obesity and type 2 diabetes. The findings add evidence for treating these overlapping conditions, but do not establish that the investigational medicine prevents cardiovascular events or extends healthy lifespan.

The European Association for the Study of Diabetes announced the findings alongside their September 29 publication in The Lancet. Lilly had already disclosed headline results in July; this week's development is the fuller account of the trial, rather than the first announcement that it met its weight-loss endpoint.

What the trial measured

The Lilly-sponsored study randomly assigned 1,152 adults to three retatrutide groups or placebo for 80 weeks. Its double-blind design meant participants and investigators were masked to treatment assignment. The principal weight-management endpoint was percentage change in body weight; change in HbA1c, a measure of longer-term blood glucose, was a key secondary endpoint.

According to the diabetes association's research summary, participants averaged approximately 55 years of age and had a mean body mass index of 38.2. Most were already taking oral glucose-lowering medicines. This was therefore a study of people with established metabolic disease, rather than a prevention trial in otherwise healthy adults.

The association reported average weight reductions of 11.9%, 16.8% and 18.8% across the three retatrutide groups, compared with 5.1% with placebo. In the highest-dose group, HbA1c fell by 1.45 percentage points, compared with 0.45 points with placebo.

Why two weight-loss figures appear

Lilly's announcement emphasizes a larger figure: 20.8% average weight loss in the highest-dose group, versus 4.0% with placebo. That estimate answers a different statistical question.

The company's figures use an “efficacy estimand,” which estimates results if participants remained on study treatment without starting prohibited weight-management treatments. The published TRIUMPH program design also specifies a treatment-regimen estimand, intended to assess effects regardless of treatment discontinuation or use of prohibited treatments.

These approaches address different aspects of a medicine's performance. An estimate assuming continued treatment helps describe efficacy under those conditions. An analysis incorporating discontinuation better captures the consequences of assigning treatment when some participants cannot or do not continue it. Neither figure should be presented as a guaranteed individual outcome or compared casually with results from unrelated trials.

Tolerability and the remaining questions

Gastrointestinal adverse events were common. The diabetes association reported diarrhea in approximately 27%–34% of retatrutide recipients, versus 13% with placebo, and nausea in 14%–28%, versus 8%. These effects matter when interpreting how sustained treatment might work outside a controlled study.

Retatrutide activates receptors for three hormones: GIP, GLP-1 and glucagon. Its mechanism and the trial's metabolic improvements make it relevant to research on chronic disease and healthspan. However, changes in weight, glucose and cardiovascular risk markers cannot by themselves demonstrate fewer heart attacks, less disability or longer survival.

The placebo comparison also does not establish superiority over existing medicines. Longer observation and trials measuring clinical events are needed to clarify benefits and risks beyond the outcomes reported here. Generalization to frail older adults likewise requires evidence specific to that population.

Lilly says it plans a U.S. regulatory submission in the first quarter of 2027. Retatrutide remains investigational; the current results support further evaluation rather than an assumption of approval or established longevity benefit.